NASDAQ:XOMA

XOMA Competitors

$35.44
-0.57 (-1.58 %)
(As of 04/20/2021 05:17 PM ET)
Add
Compare
Today's Range
$35.28
Now: $35.44
$36.35
50-Day Range
$33.21
MA: $38.06
$40.91
52-Week Range
$15.48
Now: $35.44
$46.32
Volume16,063 shs
Average Volume54,590 shs
Market Capitalization$398.98 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26

Competitors

XOMA (NASDAQ:XOMA) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying XOMA stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to XOMA, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

XOMA (NASDAQ:XOMA) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares XOMA and Amgen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA$18.37 million21.72$-1,980,000.00($0.23)-154.09
Amgen$23.36 billion6.39$7.84 billion$14.8217.49

Amgen has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

57.2% of XOMA shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 9.9% of XOMA shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for XOMA and Amgen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
XOMA00203.00
Amgen091402.61

XOMA currently has a consensus target price of $46.00, suggesting a potential upside of 29.80%. Amgen has a consensus target price of $261.1429, suggesting a potential upside of 0.77%. Given XOMA's stronger consensus rating and higher probable upside, analysts plainly believe XOMA is more favorable than Amgen.

Profitability

This table compares XOMA and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XOMA-102.23%-28.83%-11.91%
Amgen29.42%95.55%15.52%

Risk and Volatility

XOMA has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Summary

Amgen beats XOMA on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and XOMA (NASDAQ:XOMA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Risk & Volatility

Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, XOMA has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Gilead Sciences and XOMA, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191302.52
XOMA00203.00

Gilead Sciences currently has a consensus price target of $97.68, suggesting a potential upside of 47.51%. XOMA has a consensus price target of $46.00, suggesting a potential upside of 29.80%. Given Gilead Sciences' higher possible upside, equities research analysts clearly believe Gilead Sciences is more favorable than XOMA.

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 57.2% of XOMA shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 9.9% of XOMA shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Gilead Sciences and XOMA's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.72$5.39 billion$6.1410.81
XOMA$18.37 million21.72$-1,980,000.00($0.23)-154.09

Gilead Sciences has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and XOMA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
XOMA-102.23%-28.83%-11.91%

Summary

Gilead Sciences beats XOMA on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and XOMA (NASDAQ:XOMA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 57.2% of XOMA shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 9.9% of XOMA shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Vertex Pharmaceuticals and XOMA, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
XOMA00203.00

Vertex Pharmaceuticals currently has a consensus price target of $293.2083, indicating a potential upside of 33.24%. XOMA has a consensus price target of $46.00, indicating a potential upside of 29.80%. Given Vertex Pharmaceuticals' higher probable upside, equities research analysts plainly believe Vertex Pharmaceuticals is more favorable than XOMA.

Profitability

This table compares Vertex Pharmaceuticals and XOMA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
XOMA-102.23%-28.83%-11.91%

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, XOMA has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and XOMA's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.69$1.18 billion$4.2951.32
XOMA$18.37 million21.72$-1,980,000.00($0.23)-154.09

Vertex Pharmaceuticals has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats XOMA on 11 of the 15 factors compared between the two stocks.

XOMA (NASDAQ:XOMA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Valuation and Earnings

This table compares XOMA and Regeneron Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA$18.37 million21.72$-1,980,000.00($0.23)-154.09
Regeneron Pharmaceuticals$7.86 billion6.87$2.12 billion$21.4723.49

Regeneron Pharmaceuticals has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares XOMA and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XOMA-102.23%-28.83%-11.91%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Analyst Recommendations

This is a summary of current ratings for XOMA and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
XOMA00203.00
Regeneron Pharmaceuticals051412.80

XOMA currently has a consensus target price of $46.00, suggesting a potential upside of 29.80%. Regeneron Pharmaceuticals has a consensus target price of $644.1739, suggesting a potential upside of 27.70%. Given XOMA's stronger consensus rating and higher possible upside, equities analysts clearly believe XOMA is more favorable than Regeneron Pharmaceuticals.

Volatility & Risk

XOMA has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Insider & Institutional Ownership

57.2% of XOMA shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 9.9% of XOMA shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats XOMA on 11 of the 15 factors compared between the two stocks.

XOMA (NASDAQ:XOMA) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Volatility & Risk

XOMA has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares XOMA and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XOMA-102.23%-28.83%-11.91%
Biogen35.63%51.00%23.54%

Analyst Recommendations

This is a summary of recent recommendations for XOMA and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
XOMA00203.00
Biogen5141202.23

XOMA currently has a consensus price target of $46.00, suggesting a potential upside of 29.80%. Biogen has a consensus price target of $303.3103, suggesting a potential upside of 11.07%. Given XOMA's stronger consensus rating and higher probable upside, equities research analysts plainly believe XOMA is more favorable than Biogen.

Institutional and Insider Ownership

57.2% of XOMA shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 9.9% of XOMA shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares XOMA and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA$18.37 million21.72$-1,980,000.00($0.23)-154.09
Biogen$14.38 billion2.89$5.89 billion$33.578.14

Biogen has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats XOMA on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and XOMA (NASDAQ:XOMA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, XOMA has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 57.2% of XOMA shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by insiders. Comparatively, 9.9% of XOMA shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Alexion Pharmaceuticals and XOMA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017412.27
XOMA00203.00

Alexion Pharmaceuticals currently has a consensus target price of $153.4286, indicating a potential downside of 7.87%. XOMA has a consensus target price of $46.00, indicating a potential upside of 29.80%. Given XOMA's stronger consensus rating and higher probable upside, analysts plainly believe XOMA is more favorable than Alexion Pharmaceuticals.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and XOMA's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.37$2.40 billion$9.7417.10
XOMA$18.37 million21.72$-1,980,000.00($0.23)-154.09

Alexion Pharmaceuticals has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alexion Pharmaceuticals and XOMA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
XOMA-102.23%-28.83%-11.91%

Summary

Alexion Pharmaceuticals beats XOMA on 11 of the 15 factors compared between the two stocks.


XOMA Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$259.14-1.2%$149.21 billion$23.36 billion20.90Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.38-0.6%$83.58 billion$22.45 billion68.43Analyst Report
Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$220.16-0.4%$56.98 billion$4.16 billion27.80Analyst Report
Analyst Revision
News Coverage
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$504.42-0.9%$54.04 billion$7.86 billion18.44Analyst Report
Biogen logo
BIIB
Biogen
1.9$273.20-1.5%$41.62 billion$14.38 billion9.04Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$166.54-0.6%$36.79 billion$4.99 billion38.91News Coverage
Seagen logo
SGEN
Seagen
1.7$144.76-0.5%$26.11 billion$916.71 million56.99Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$125.62-1.5%$21.24 billion$876.29 million-56.84Analyst Upgrade
Incyte logo
INCY
Incyte
1.7$84.57-2.2%$18.59 billion$2.16 billion-53.87
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$136.03-1.0%$16.12 billion$219.75 million-17.37Analyst Report
Novavax logo
NVAX
Novavax
1.4$208.15-6.4%$15.37 billion$18.66 million-39.88Insider Selling
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$79.45-0.2%$14.47 billion$1.70 billion18.18Analyst Report
News Coverage
Repligen logo
RGEN
Repligen
1.5$211.99-0.0%$11.61 billion$270.24 million258.52Analyst Report
News Coverage
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.16-1.4%$9.09 billion$788.10 million103.40Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$207.58-1.8%$9.08 billion$1.45 billion19.64
Exelixis logo
EXEL
Exelixis
1.9$24.51-3.1%$7.67 billion$967.78 million51.06Analyst Report
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.83-1.6%$6.71 billion$195.99 million292.69
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.16-3.0%$5.80 billion$1.12 billion85.75Analyst Report
Analyst Revision
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$66.76-2.1%$4.03 billion$806.43 million-9.46Analyst Report
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$65.62-3.4%$3.52 billion$1.11 billion21.10News Coverage
Alkermes logo
ALKS
Alkermes
1.2$20.16-0.5%$3.19 billion$1.17 billion-43.83Analyst Revision
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$45.29-1.1%$3.12 billion$36.13 million-67.60
OPKO Health logo
OPK
OPKO Health
1.9$4.13-1.7%$2.77 billion$901.90 million-22.94
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.78-1.2%$2.62 billion$182.24 million-8.50Analyst Upgrade
Insider Selling
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$146.76-0.5%$2.44 billion$120.28 million-148.24Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$26.61-2.3%$2.05 billion$638.60 million-10.23
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.11-3.6%$1.97 billion$48.83 million-14.62
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$126.33-4.1%$1.94 billionN/A-11.41News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.66-0.5%$1.71 billion$428.41 million15.45Analyst Upgrade
News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.53-1.9%$1.66 billion$102.43 million-19.22Analyst Upgrade
Codexis logo
CDXS
Codexis
1.3$22.89-1.4%$1.47 billion$68.46 million-65.40Analyst Report
News Coverage
Gap Up
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.32-1.2%$1.46 billion$82.27 million-17.85News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.98-0.8%$1.21 billion$261.02 million6.11
MannKind logo
MNKD
MannKind
1.4$4.23-1.7%$1.05 billion$63.04 million-20.14Increase in Short Interest
News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.94-21.8%$1.01 billion$35.22 million-6.53Gap Up
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$23.67-2.0%$937.69 million$3.57 million-10.61
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.55-0.7%$908.31 million$227.19 million45.97Analyst Downgrade
Curis logo
CRIS
Curis
1.3$9.82-5.0%$898.72 million$10 million-11.98News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.34-0.2%$882.77 millionN/A0.00
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.88-0.8%$704.45 million$322.07 million-4.65Upcoming Earnings
Decrease in Short Interest
News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17-0.9%$682.20 million$150,000.00-4.53News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.80-2.9%$666.59 million$252 million-2.13
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.67-1.9%$604.18 million$143.01 million-1.08
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.55-2.0%$603.93 million$59.29 million-23.67Increase in Short Interest
News Coverage
Agenus logo
AGEN
Agenus
1.6$2.68-4.1%$547.53 million$150.05 million-2.45
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.96-4.1%$464.67 million$22.27 million-3.90Analyst Revision
News Coverage
Verastem logo
VSTM
Verastem
1.3$2.71-0.4%$463.50 million$17.46 million-1.92
Geron logo
GERN
Geron
1.4$1.40-0.0%$445.94 million$460,000.00-4.00Decrease in Short Interest
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.91-0.7%$444.27 million$109.33 million-2.14
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$4.01-1.0%$380.58 million$36.63 million-4.72Analyst Report
Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.